Roche Holding AG (Roche Holding AG) FCF Margin %

: 18.51% (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Roche Holding AG's Free Cash Flow for the six months ended in Dec. 2023 was $6,385 Mil. Roche Holding AG's Revenue for the six months ended in Dec. 2023 was $34,488 Mil. Therefore, Roche Holding AG's FCF Margin % for the quarter that ended in Dec. 2023 was 18.51%.

As of today, Roche Holding AG's current FCF Yield % is 6.68%.

The historical rank and industry rank for Roche Holding AG's FCF Margin % or its related term are showing as below:

RHHBY' s FCF Margin % Range Over the Past 10 Years
Min: 18.93 Med: 24.53 Max: 28.45
Current: 18.93

During the past 13 years, the highest FCF Margin % of Roche Holding AG was 28.45%. The lowest was 18.93%. And the median was 24.53%.

RHHBY's FCF Margin % is ranked better than
89.36% of 1024 companies
in the Drug Manufacturers industry
Industry Median: -0.68 vs RHHBY: 18.93

Roche Holding AG FCF Margin % Historical Data

The historical data trend for Roche Holding AG's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

28.45

20.36

26.16

20.13

18.94

Roche Holding AG Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %																32.13	21.08	19.13	19.35	18.51

Competitive Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roche Holding AG FCF Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's FCF Margin % falls into.

Roche Holding AG FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Roche Holding AG's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	13235.431	/	69890.148
	=	18.94 %

Roche Holding AG's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	6385.291	/	34487.743
	=	18.51 %

Roche Holding AG FCF Margin % Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Roche Holding AG (Roche Holding AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

RHHVF:USA RHHBF:USA ROG N:Mexico ROz:UK ROGz:UK 0QOK:UK RHO6:Germany ROG:Switzerland RO:Switzerland

Address

Grenzacherstrasse 124, Basel, CHE, 4070

Website

https://www.roche.com

Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.